m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03208
 [1]
Histone modification H3K27ac p300 CDC42 Direct Enhancement m6A modification CDC42 CDC42 HNRNPA2B1 : m6A sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) READER
 Regulator Info 
m6A Target Cell division control protein 42 homolog (CDC42)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone acetyltransferase p300 (P300) WRITER View Details
Regulated Target Histone H3 lysine 27 acetylation (H3K27ac) View Details
Downstream Gene CDC42 View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification regulates m6A modification through both regulatory proteins targeting the same gene
Crosstalk Summary LINC00355 binds to p300 histone acetyltransferase, specifying Histone H3 lysine 27 acetylation (H3K27ac) modification pattern on the Cell division control protein 42 homolog (CDC42) promoter to activate CDC42 transcription, thereby altering GC cell biology. In addition, HNRNPA2B1, which is upregulated by LINC00355, recognizes the N6-methyladenosine (m6A) sites of CDC42 and enhances the stability of CDC42 mRNA transcripts. Therefore, LINC00355 is mechanistically, functionally, and clinically oncogenic in GC cells.
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
In-vitro Model
 BGC-823 Gastric carcinoma Homo sapiens CVCL_3360
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
MGC-803 Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
AGS Gastric adenocarcinoma Homo sapiens CVCL_0139
In-vivo Model Xenograft mouse tumor model was established by inoculating MKN-45 cells transfected with LV Sh355 lentivirus or control LV ShNC lentivirus (2 × 106 in 200 μl sterile 1×phosphate-buffered saline [PBS]) subcutaneously into the right armpit of 5-6-week-old male BALB/c nude mice. GC pulmonary metastatic model was established by injecting MKN-45 cells transfected with LV Sh355 lentivirus or control LV ShNC lentivirus (2 × 106 in 200 μl sterile 1 × PBS) into the caudal vein of 5-6-week-old male BALB/c nude mice
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone acetyltransferase p300 (P300) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CCS1477 Phase 1/2 [2]
Synonyms
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 134457551
TTD: DIY4C2
 Compound Name FT-7051 Phase 1 [3]
MOA Inhibitor
External Link
TTD: DT8IL6
2B72: Gastric cancer 81 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Leniolisib Approved [4]
Synonyms
1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ
    Click to Show/Hide
External Link
CID: 57495353
TTD: DGO2C1
 Compound Name Atezolizumab Approved [5]
External Link
TTD: D0YM2K
 Compound Name Bavencio Approved [5]
External Link
TTD: D0W8HN
 Compound Name Tebentafusp Approved [6]
External Link
TTD: D0S0BJ
 Compound Name Merimepodib Approved [7]
Synonyms
Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
    Click to Show/Hide
External Link
CID: 153241
TTD: D0F0ZE
DrugBank: DB04862
 Compound Name Taxol Approved [8]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Ramucirumab Approved [9]
Synonyms
LY3009806
    Click to Show/Hide
External Link
TTD: D09HVD
 Compound Name Tucatinib Approved [10]
Synonyms
Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
    Click to Show/Hide
External Link
CID: 51039094
TTD: D09GRX
DrugBank: DB11652
 Compound Name Antacids Approved [11]
External Link
TTD: D06AJL
 Compound Name Trastuzumab Approved [5]
Synonyms
Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
    Click to Show/Hide
External Link
TTD: D04WFL
 Compound Name Carbamazepine Phase 3 [12]
Synonyms
Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
    Click to Show/Hide
External Link
CID: 2554
TTD: D04MSM
DrugBank: DB00564
 Compound Name Margetuximab Approved [5]
External Link
TTD: D01YYP
 Compound Name Nivolumab Approved [5]
External Link
TTD: D00GOV
 Compound Name GRANITE Phase 3 [13]
Synonyms
Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-
    Click to Show/Hide
External Link
CID: 11784975
TTD: DKF9I3
 Compound Name Zolbetuximab Phase 3 [14]
Synonyms
IMAB362
    Click to Show/Hide
External Link
TTD: D4HQ1F
 Compound Name Tusamitamab ravtansine Phase 3 [15]
Synonyms
SAR408701
    Click to Show/Hide
External Link
TTD: D2D6NJ
 Compound Name Andecaliximab Phase 3 [16]
External Link
TTD: D0Z6SP
 Compound Name ABP 980 Phase 3 [17]
External Link
TTD: D0WZ0X
 Compound Name GS-5745 Phase 3 [8]
External Link
CID: 56776542
TTD: D0WL0Q
 Compound Name S-1 Phase 3 [18]
Synonyms
Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)
    Click to Show/Hide
External Link
CID: 163872
TTD: D0S8LJ
 Compound Name Lonsurf Phase 3 [5]
External Link
TTD: D0PM0Y
 Compound Name GDC-0068 Phase 3 [8]
Synonyms
RG7440
    Click to Show/Hide
External Link
CID: 24788740
TTD: D0I4TH
DrugBank: DB11743
 Compound Name Edotecarin Phase 3 [19]
Synonyms
ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
    Click to Show/Hide
External Link
CID: 9808998
TTD: D0I1DW
DrugBank: DB04882
 Compound Name RG3638 Phase 3 [20]
Synonyms
Onartuzumab
    Click to Show/Hide
External Link
TTD: D0H9PT
 Compound Name G17DT Phase 3 [21]
Synonyms
Gastrimmune; Insegia
    Click to Show/Hide
External Link
TTD: D0G8ZQ
 Compound Name DE-766 Phase 3 [22]
External Link
TTD: D0FJ1W
 Compound Name Tesetaxel Phase 2 [23]
Synonyms
DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
    Click to Show/Hide
External Link
CID: 6918574
TTD: D0F9VH
DrugBank: DB12019
 Compound Name Nelipepimut S Phase 3 [24]
Synonyms
E75
    Click to Show/Hide
External Link
CID: 9941306
TTD: D0F8UV
 Compound Name BMS-986205 Phase 3 [5]
Synonyms
KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
    Click to Show/Hide
External Link
CID: 121328278
TTD: D0DP5I
DrugBank: DB14986
 Compound Name Rivoceranib Phase 3 [5]
External Link
TTD: D0D7BX
 Compound Name Claudiximab Phase 3 [5]
Synonyms
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
    Click to Show/Hide
External Link
TTD: D0B3ZC
 Compound Name OS-440 Phase 3 [25]
Synonyms
CNS modulator (spasticity), Osmotica
    Click to Show/Hide
External Link
TTD: D09OHH
 Compound Name Oraxol Phase 3 [5]
External Link
TTD: D04UWU
 Compound Name ICI 118,551 Phase 3 [8]
Synonyms
Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
    Click to Show/Hide
External Link
CID: 3682
TTD: D04DJS
 Compound Name Evorpacept Phase 2/3 [26]
Synonyms
ALX148
    Click to Show/Hide
External Link
TTD: DRP8H0
 Compound Name BNT141 Phase 2 [27]
External Link
TTD: DFZ19J
 Compound Name Anti-LAG3 Phase 2 [17]
External Link
TTD: D0T7OI
 Compound Name GSK1292263 Phase 2 [28]
External Link
CID: 24996872
TTD: D0S4II
DrugBank: DB12627
 Compound Name MM-111 Phase 2 [29]
External Link
TTD: D0Q2KM
 Compound Name Plevitrexed Phase 2 [30]
Synonyms
ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,
    Click to Show/Hide
External Link
CID: 135430970
TTD: D0I9GR
DrugBank: DB06163
 Compound Name DS-8201 Phase 1 [17]
Synonyms
9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-
    Click to Show/Hide
External Link
CID: 10671
TTD: D0E8IQ
 Compound Name XL880 Phase 2 [31]
Synonyms
GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
    Click to Show/Hide
External Link
CID: 42642645
TTD: D0D1GF
DrugBank: DB12307
 Compound Name Matuzumab Phase 2 [32]
Synonyms
EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0BZ7V
 Compound Name BAY-57-9352 Phase 2 [8]
Synonyms
Telatinib; Bay 57-9352
    Click to Show/Hide
External Link
CID: 9808844
TTD: D07NOI
DrugBank: DB15393
 Compound Name Bemarituzumab Phase 2 [33]
External Link
TTD: D05ISO
 Compound Name PEGPH20 Phase 2 [5]
External Link
TTD: D05INV
 Compound Name Plevitrexed (R)-isomer Phase 2 [34]
Synonyms
YW3548
    Click to Show/Hide
External Link
CID: 213022
TTD: D04FYZ
 Compound Name APR-246 Phase 2 [35]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name CRS-207 Phase 2 [24]
External Link
TTD: D02WSB
 Compound Name Opdivo + Yervoy Phase 3 [5]
External Link
TTD: D02VYE
 Compound Name CT-041 Phase 1/2 [36]
External Link
TTD: DJ6AW5
 Compound Name BPX-601 Phase 1/2 [37]
External Link
TTD: D0TY6U
 Compound Name Anti-MUC1 CAR-T cells Phase 1/2 [38]
External Link
TTD: D0C9MJ
 Compound Name Anti-Mesothelin CAR-T cells Phase 1/2 [39]
External Link
TTD: D0BE6M
 Compound Name Anti-HER2 CAR-T Phase 1/2 [40]
External Link
TTD: D08QZH
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [41]
External Link
TTD: D08QYW
 Compound Name PAT-SC1 Phase 1/2 [42]
Synonyms
SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab
    Click to Show/Hide
External Link
TTD: D00UOQ
 Compound Name ASP2138 Phase 1 [43]
External Link
TTD: DTQL30
 Compound Name SAR443216 Phase 1 [44]
External Link
TTD: DL6F3E
 Compound Name AMG 199 Phase 1 [45]
External Link
TTD: DEP3Z8
 Compound Name AMG 910 Phase 1 [46]
External Link
TTD: DEDP81
 Compound Name Alofanib Phase 1 [47]
Synonyms
1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
    Click to Show/Hide
External Link
CID: 86280646
TTD: D47MOS
 Compound Name HER2-specific CAR T cell Phase 1 [48]
External Link
TTD: D0YF6K
 Compound Name Anti-CEA-CAR T Phase 1 [49]
External Link
TTD: D0S1QN
 Compound Name XR-5944 Phase 1 [50]
Synonyms
MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942
    Click to Show/Hide
External Link
CID: 439035
TTD: D0Q5TH
DrugBank: DB06364
 Compound Name A168 Phase 1 [51]
External Link
TTD: D0L9PU
 Compound Name EGFR806-specific CAR T cell Phase 1 [52]
External Link
TTD: D0I7ZH
 Compound Name AbGn-107 Phase 1 [5]
External Link
TTD: D08GZE
 Compound Name FPA144 Phase 1 [17]
External Link
TTD: D06NND
 Compound Name Minnelide 001 Phase 1 [8]
External Link
TTD: D05UFJ
 Compound Name CAR-T cells targeting EpCAM Phase 1 [53]
External Link
TTD: D01TNK
 Compound Name Anti-CEA CAR-T cells Phase 1 [54]
External Link
TTD: D00KDQ
 Compound Name EPCAM-targeted CAR-T cells Clinical trial [55]
External Link
TTD: D0T8DD
 Compound Name PMID28460551-Compound-1 Patented [56]
External Link
CID: 25190990
TTD: D0IH3I
DrugBank: DB14866
 Compound Name Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 Patented [57]
Synonyms
PMID28621580-Compound-WO2012084683c62
    Click to Show/Hide
External Link
TTD: D04PKQ
 Compound Name TOPIXANTRONE HYDROCHLORIDE Discontinued in Phase 2 [58]
Synonyms
SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride
    Click to Show/Hide
External Link
CID: 6918273
TTD: D06DWQ
 Compound Name MDL 101,731 Discontinued in Phase 2 [59]
Synonyms
Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331
    Click to Show/Hide
External Link
CID: 6435808
TTD: D05HZI
DrugBank: DB06433
 Compound Name BBR-3438 Discontinued in Phase 2 [60]
Synonyms
Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438
    Click to Show/Hide
External Link
CID: 3038512
TTD: D01VPR
 Compound Name IPI-493 Discontinued in Phase 1 [61]
Synonyms
[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851
    Click to Show/Hide
External Link
CID: 9893658
TTD: D0BM6S
DrugBank: DB13023
 Compound Name Kanjinti Application submitted [5]
External Link
TTD: D0CW3U
 Compound Name Anti-CD9 mab Investigative [62]
Synonyms
ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University
    Click to Show/Hide
External Link
TTD: D09BPT
References
Ref 1 LINC00355 promotes gastric carcinogenesis by scaffolding p300 to activate CDC42 transcription and enhancing HNRNPA2B1 to stabilize CDC42 mRNA dependent on m6A. Mol Carcinog. 2024 Mar;63(3):430-447. doi: 10.1002/mc.23662. Epub 2023 Nov 20.
Ref 2 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11.
Ref 3 Clinical pipeline report, company report or official report of FORMA Therapeutics.
Ref 4 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217759.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228.
Ref 7 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7390).
Ref 10 ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
Ref 11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 12 ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT00879333) Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). U.S. National Institutes of Health.
Ref 14 ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
Ref 15 ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.
Ref 16 ClinicalTrials.gov (NCT02545504) Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1). U.S. National Institutes of Health.
Ref 17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 18 Clinical pipeline report, company report or official report of Taiho Pharma U.S.A.
Ref 19 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
Ref 20 ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.
Ref 21 ClinicalTrials.gov (NCT02118077) Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 22 Clinical pipeline report, company report or official report of Daiichi Sankyo.
Ref 23 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 25 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031678)
Ref 26 ClinicalTrials.gov (NCT05002127) A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). U.S.National Institutes of Health.
Ref 27 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 28 ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.
Ref 29 ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
Ref 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8278).
Ref 31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
Ref 32 ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
Ref 33 ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
Ref 34 Clinical pipeline report, company report or official report of plevitrexed.
Ref 35 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT04404595) Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers. U.S.National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 38 ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Ref 39 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 40 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 41 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013314)
Ref 43 ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
Ref 44 Clinical pipeline report, company report or official report of Sanofi
Ref 45 ClinicalTrials.gov (NCT04117958) Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
Ref 46 ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT04071184) Study of Alofanib in Patients With Metastatic Gastric Cancer. U.S. National Institutes of Health.
Ref 48 ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Ref 49 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 50 Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
Ref 51 Clinical pipeline report, company report or official report of Klus Pharma
Ref 52 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Ref 53 ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
Ref 54 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 55 ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
Ref 56 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 57 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. doi: 10.1080/13543776.2017.1344215. Epub 2017 Jun 23.
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
Ref 59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002544)
Ref 60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)
Ref 61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026781)
Ref 62 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.